Myeloproliferative Neoplasms

FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS
April 06, 2020
ByKristie L. Kahl

The FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

Patient Outcomes After Stopping Ruxolitinib Remains Dismal in Myelofibrosis
January 17, 2020
ByHannah Slater

This study highlighted the need for novel therapies in myelofibrosis treatment, given that salvage therapies could potentially improve patient outcomes.

Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies
May 15, 2018
ByKelsey Sokol, MD|Douglas Tremblay, MD|Sheena Bhalla, MD|Raajit Rampal, MD|John O. Mascarenhas, MD

In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.